GIP/GLP-1 & amylin agonists × body weight & composition

TrialJournal of the American College of Cardiology2025

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Christopher M Kramer et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 175 people · 2025

Randomised comparison

Probably lowered body weight & composition

−45.0mL−69.0 to −22.0

As reported

difference −45.0 mL, 95% CI −69.0 to −22.0

One number in the abstract

the abstract, start to end

tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−45.0−69.0 to −22.0
GIP/GLP-1 & amylin agonistsBody weight & composition

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

85 papers cite itlatest 60 shown

2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 39566869